CMS Counted 450 Medicaid Quality Reporting Requirements for 260 Measures, and 37 States Pledged to Streamline Them
The pledge sets a direction without a single measure, target or date. The lever that will matter is managed care procurement.
Quick
The daily shorts. One story, one insight.
FOP Now Has Three Approved Drugs for About 300 US Patients, Two of Them in 37 Days
Three drugs now divide an ultra-rare disease by mechanism, route and age, and the newest competes on convenience and safety.
AbbVie Largely Dropped Its Constitutional Case but Still Says Botox Is Plasma-Derived and Exempt
Constitutional challenges to Medicare negotiation have failed repeatedly. AbbVie is now betting on the definition of its product.
Europe Approved Leriglitazone for Boys With cALD Two Years After the EMA Recommended Refusal
A drug the EMA refused two years ago is now approved, on a narrow label and under exceptional circumstances, with Europe first.
Genentech Bets $1.5B+ on Earendil’s Bispecifics With $55M Upfront
The one clean upfront among this week’s discovery deals, and Earendil keeps more of the early clinical risk than most.
Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront
QuickDeal read/Deals Lilly, InnoCare Strike $3.35B Pact, Heavy on Milestones, Light on Upfront Athithi Verma· 24 September 2026· 2 min read· Synopulse InnoCare Pharma, listed in Hong Kong and Shanghai, said on 24 September 2026 that it has signed a strategic research collaboration and licence agreement with Eli Lilly. InnoCare will use its discovery platform … Read more
Henlius Licensed a US pH-Switch Platform for Two T-Cell Engager Targets Without Disclosing Any Payment
Henlius bought a switch, not a molecule, and the deal discloses no dollar figure at all, not even a headline total.
Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria
Sefaxersen hits the same target as Novartis’s Fabhalta. Roche withheld the one number that would show which drug does more.
A Court Vacated the FDA’s Biologic Classification of MiMedx’s Wound Powder Because Similar Products Were Devices
The court did not rule on what AXIOFILL is. It ruled that FDA had not treated like wound care products alike.
Plaintiffs Say CMS’ Frailty Rule Raises Projected Medicaid Losses From 6.4 Million to 8.2 Million a Year
Congress named who is medically frail. CMS’s rule decides who can prove it, and the new lawsuit is about that gap.